CNSP · Cns Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $3.54M | - | $2.20M | $1.17M | $3.24M | - | $4.24M | $1.12M | $2.43M | - |
| SG&A | $1.43M | - | $1.06M | $1.24M | $1.09M | - | $1.38M | $1.41M | $1.11M | - |
| Total Operating Expenses | $4.98M | - | $3.25M | $2.41M | $4.34M | - | $5.63M | $2.53M | $3.54M | - |
| D&A | $1.9K | - | - | - | $1.1K | - | - | - | $818 | - |
| Operating Income | ($4.98M) | - | ($3.25M) | ($2.41M) | ($4.34M) | - | ($5.63M) | ($2.53M) | ($3.54M) | - |
| Interest Expense | $6.1K | - | $2.1K | $4.2K | $6.6K | - | $1.8K | $4.5K | $6.6K | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($4.94M) | - | ($3.22M) | ($2.37M) | ($4.30M) | - | ($5.61M) | ($2.53M) | ($3.54M) | - |
| EPS - Basic | ($7.30) | - | ($5.76) | ($6.42) | ($18.96) | - | ($150.00) | ($4032.00) | ($12300.00) | - |
| EPS - Diluted | ($7.30) | - | ($5.76) | ($6.42) | ($18.96) | - | ($150.00) | ($4032.00) | ($12300.00) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.95M | $7.20M | $9.86M | $12.13M | $13.05M | $6.46M | $6.97M | $1.49M | $815.2K | $548.7K |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | - | - | - | - | - | - | - | - | - | - |
| Current Assets | $4.08M | $8.10M | $11.39M | $14.14M | $13.72M | $8.66M | $7.39M | $2.15M | $1.60M | $1.59M |
| Total Assets | $4.65M | $8.62M | $11.87M | $14.51M | $13.75M | $8.70M | $7.41M | $2.47M | $1.66M | $1.70M |
| Current Liabilities | $4.58M | $4.10M | $1.96M | $1.38M | $2.78M | $2.52M | $4.06M | $6.76M | $6.09M | $6.13M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $4.58M | $4.10M | $1.96M | $1.38M | $2.78M | $2.52M | $4.06M | $6.76M | $6.09M | $6.13M |
| Stockholders' Equity | $70.7K | $4.52M | $9.91M | $13.12M | $10.97M | $6.18M | $3.35M | ($4.29M) | ($4.43M) | ($4.43M) |
| Retained Earnings | ($105.21M) | ($100.28M) | ($94.32M) | ($91.10M) | ($88.73M) | ($84.42M) | ($81.25M) | ($75.64M) | ($73.11M) | ($69.57M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($4.65M) | - | - | - | ($3.24M) | - | - | - | ($3.19M) | - |
| Investing Cash Flow | $0 | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | $404.7K | - | - | - | $9.83M | - | - | - | $3.46M | - |
| CapEx | $6.2K | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | ($4.65M) | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.94 | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -106.1% | - | -27.1% | -16.4% | -31.3% | - | -75.7% | -102.5% | -213.4% | - |
| Return on equity | -6982.6% | - | -32.5% | -18.1% | -39.2% | - | -167.2% | 58.9% | 80.0% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.89 | 1.98 | 5.81 | 10.22 | 4.94 | 3.43 | 1.82 | 0.32 | 0.26 | 0.26 |
| Quick ratio | 0.89 | 1.98 | 5.81 | 10.22 | 4.94 | 3.43 | 1.82 | 0.32 | 0.26 | 0.26 |
| Cash ratio | 0.64 | 1.76 | 5.03 | 8.77 | 4.69 | 2.56 | 1.72 | 0.22 | 0.13 | 0.09 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -814.1x | - | -1537.5x | -575.7x | -654.7x | - | -3062.5x | -566.5x | -535.1x | - |
| Equity multiplier | 65.81 | 1.91 | 1.20 | 1.11 | 1.25 | 1.41 | 2.21 | -0.58 | -0.37 | -0.38 |
| Liabilities / Assets | 0.98 | 0.48 | 0.17 | 0.10 | 0.20 | 0.29 | 0.55 | 2.74 | 3.67 | 3.61 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 22.9x | - | 0.5x | 0.3x | 4.1x | - | 520.1x | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -14.7% | - | 42.2% | 4.7% | -22.4% | - | -24.2% | 37.2% | 28.0% | - |
| Net income growth (YoY) | -14.8% | - | 42.6% | 6.2% | -21.3% | - | -23.9% | 37.1% | 28.1% | - |
| EPS growth (YoY) | 61.5% | - | 96.2% | 99.8% | 99.8% | - | -13788.9% | -387592.3% | -474803.5% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -99.4% | -26.8% | 195.6% | - | - | - | - | - | - | - |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing CNS Pharmaceuticals against the 5 most active filers in the same SIC group.